MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-23-2025
Medpace Holdings Depreciation & Amortization 2011-2026 | MEDP
Annual Depreciation & Amortization Medpace Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.8 M | 24.1 M | 19 M | 16 M | 11.7 M | 8.36 M | 9.24 M | 8.57 M | 7.44 M | 6.38 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.8 M | 6.38 M | 13.9 M |
Quarterly Depreciation & Amortization Medpace Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.81 M | 6.78 M | 6.69 M | - | 7.16 M | 6.87 M | 6.63 M | - | 6.33 M | 5.97 M | 5.41 M | - | 4.95 M | 4.71 M | 4.27 M | - | 4.06 M | 3.95 M | 3.81 M | - | 2.99 M | 2.67 M | 2.45 M | - | 2.06 M | 1.98 M | 1.99 M | - | 2.34 M | 2.23 M | 2.31 M | - | 2.24 M | 2.1 M | 2.13 M | - | 1.92 M | 1.79 M | 1.77 M | - | 1.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.16 M | 1.61 M | 3.84 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
264 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
47.8 M | $ 38.83 | 14.0 % | $ 442 M |  China |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 39.38 | -0.03 % | $ 1.09 B | USA |
 |
BioNano Genomics
BNGO
|
14 M | $ 1.26 | -2.69 % | $ 1.6 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Exact Sciences Corporation
EXAS
|
120 M | $ 102.49 | 0.14 % | $ 19 B | USA |
 |
Co-Diagnostics
CODX
|
1.23 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
721 M | $ 222.92 | 1.85 % | $ 163 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M | China |
 |
Guardant Health
GH
|
42.4 M | $ 114.77 | 0.64 % | $ 14.1 B | USA |
 |
DexCom
DXCM
|
186 M | $ 72.79 | -0.34 % | $ 28.1 B | USA |
 |
CareDx, Inc
CDNA
|
14.4 M | $ 20.29 | -1.27 % | $ 1.09 B | USA |
 |
Celcuity
CELC
|
130 K | $ 111.76 | 2.14 % | $ 4.41 B | USA |
 |
DarioHealth Corp.
DRIO
|
473 K | $ 10.74 | 7.19 % | $ 305 M | Israel |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 26.0 | -0.76 % | $ 786 M | USA |
 |
Lantheus Holdings
LNTH
|
64.6 M | $ 66.88 | -0.07 % | $ 4.63 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
IDEXX Laboratories
IDXX
|
130 M | $ 636.25 | -5.1 % | $ 52.5 B | USA |
 |
NeoGenomics
NEO
|
39.1 M | $ 12.25 | 1.53 % | $ 1.55 B | USA |
 |
Illumina
ILMN
|
354 M | $ 140.65 | -2.87 % | $ 22.4 B | USA |
 |
QIAGEN N.V.
QGEN
|
203 M | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
140 K | $ 21.87 | 7.5 % | $ 537 M | USA |
 |
IQVIA Holdings
IQV
|
1.11 B | $ 230.93 | 0.34 % | $ 41.9 B | USA |
 |
Charles River Laboratories International
CRL
|
362 M | $ 212.06 | 0.7 % | $ 10.9 B | USA |
 |
Precipio
PRPO
|
1.22 M | $ 24.75 | 0.9 % | $ 32.1 M | USA |
 |
Personalis
PSNL
|
10.9 M | $ 9.28 | -0.96 % | $ 550 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
493 M | $ 184.48 | -1.33 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
5.77 M | $ 10.24 | 0.69 % | $ 1.33 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
644 M | $ 269.19 | -0.86 % | $ 22.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 176.3 | -2.19 % | $ 14.5 B |  Irlanda |
 |
Agilent Technologies
A
|
321 M | $ 134.7 | 0.62 % | $ 40.9 B | USA |
 |
Biomerica
BMRA
|
87 K | $ 2.39 | 0.63 % | $ 5.49 M | USA |
 |
OpGen
OPGN
|
175 K | - | -16.95 % | $ 1.54 M | USA |
 |
Bioventus
BVS
|
57.4 M | $ 8.23 | 3.78 % | $ 516 M | USA |